Skip to main content

Table 1 Baseline chacteristics of enrolled studies

From: Meta-analysis of serum C-reactive protein and cartilage oligomeric matrix protein levels as biomarkers for clinical knee osteoarthritis

Study Design Number Age (years) Follow-up area
Fernandes, 2007 Case control KOA:75 Control: 40 KOA:56.6 ± 7.6; Control: 53.8 ± 8.5 NA Brazil
Senolt, 2005 Case control KOA:38
Control: 38
KOA:64.1 ± 10.1; Control: 58.3 ± 9.1 NA USA
Wakitani, 2007 Case control KOA:31
Control: 24
KOA:20–80; Control: 23–52 NA Japan
Li, 2012 Case control KOA:115
Control: 35
KOA:55 ± 13.2; Control:53 ± 12.53 2–3 years China
Engstrom, 2009 population-based cohort 5171 57.5 + 5.9 12.4 years Sweden
Zhang, 2015 Case control Control: 20
KOA: 20
Control:56.3 ± 7.9; KOA: 59.2 ± 8.3 NA China
Sowers, 2002 cohort 1025 42.9 ± 0.1 2.5 years USA
Kerkhof,2010 Case control KOA: 210; Control: 1360 ≥55 years NA Netherlands
Haghighian,2014 Case control 23 58.27 ± 7.84 2 months Iran
Ramirez, 2014 cohort 186 61 ± 7.3 2 years Netherlands
Nielsen, 2014 Case control 281 40–80 NA Denmark
Scorei, 2011 Case control 15 67.6 (5.5) 2 weeks Romania
Stannus, 2012 cohort study KOA:35; Control:114 KOA:63.2 ± 6.9 Control: 61.5 ± 6.7 5 years Australia
Hosnijeh, 2016 population-based prospective cohort 1335 65.2 (8.43) 5-year Netherlands
  1. KOA knee osteoarthritis